Fda Approves Second Round Of Coronavirus Vaccine Trials Could Reach Third Trial By Summer
“The imminent Phase 2 study start is a crucial step forward as we continue to advance the clinical development of mRNA-1273, our vaccine candidate against SARS-CoV-2,” said Stéphane Bancel, Moderna’s chief executive officer, in a statement. The company expects the upcoming trial, which will involve 600 participants, to begin shortly. In addition to confirming clearance for Phase 2, Moderna’s statement shared a timeline for ongoing plans to test, license and eventually distribute its vaccine....